Prof. Jamal Mahajna

Graduated from the Medical school at the Hebrew University under the supervision of Prof. Amos Oppenheim specialized in molecular genetics and regulation of gene expression. I am an author of more than 40 publications, including refereed research papers, review papers, chapters in books and patents. After my graduation, I joined OSI pharmaceuticals (OSIP), NY, USA and become an integral part of the cancer program working with close collaboration with scientist from Pfizer, CT, USA. 

 Currently, I am the head of the department of cancer drug discovery program at Migal, Kiryat Shmona. My main interest is in overcoming cancer drug resistance, and in particular, in Ph+ leukemia.  To overcome drug resistance caused by point mutations within BCR/ABL gene, specially the "gatekeeper" T315I mutation, we explored modulators of the Myristoyl Binding Pocket (MBP) {Khamaisie et al., 2011; Najajreh et al., 2013} and combinations approaches utilizing Abl kinase inhibitors (AKIs) with allosteric inhibitors {Khateb et al., 2012; Mian et al., 2012}. Morepver, we also addressing residual disease, cell-adhesion mediated drug resistance, and disease progression of Ph+ leukemia which is independent of BCR/ABL mutations. Specifically, we are exploring the interaction between the Ph+ leukemic cells to the bone marrow microenvironment and studying the role of epithelial-mesenchymal transition (EMT) activators in mediating homing and adhesion to the bone marrow, which is regulated by factors such as CD44, CD184, and N-cadherin that contribute to residual disease, stimulate drug resistance, and accelerate disease progression in most hematopoietic malignancies. 

In addition, we also interested in anti-cancer activity of natural products including herbs, medicinal plants and mushrooms. Our goal of using natural products or herbs is not to replace current cancer therapeutics but rather to augment their activity as adjuvants or to reduce side effects. In addition, utilizing natural products we will be able to identify novel chemical entities (NCEs) with desired activity and upon modifications and optimizing they might serve as novel cancer chemotherapeutics. 

I am a senior lecturer at the faculty of Science and biotechnology and currently I am the chairperson of the Nutritional sciences department at Tel-Hai College.

Teaching at Telhai College:

1.  Biotechnology in Medical Sciences. Biotechnology Department
2.    Laboratory in medical Sciences. Biotechnology Department
3.    Nutrition and Cancer. Nutritional Sciences Department
4.    Molecular Bases of cancer. MSC students, Biotechnology Department
5.     Nutrition for Cancer Prevention. Nutritional Sciences Department
6.   Molecular Nutrition. Nutritional Sciences Department 

• Rattray, A., Altuvia, S., Mahajna, J., Oppenheim, A., Gottesman, M. (1984) Control of Bacteriophage Lambda cII activity by Bacteriophage and Host Functions, J. Bacteriol. 159: 238-242
• Oppenheim, A.B., Mahajna, J., Koby S. and Altuvia, S. (1982) Regulation of the Establishment of Repressor Synthesis in Bacteriophage Lambda, J. Mol. Biol. 155: 121-132
• Honigman, A., Mahajna, J., Altuvia, S., Koby, S., Teff, D., Locker-Giladi, H., Hyman, H., Kroman, C., and Oppenheim, A.B. (1985) Plasmid Vectors for the Analysis of Transcription Termination signals, Gene 36: 131-141.
• Mahajna, J., Oppenheim, A.B., Rattray, A., and Gottesman, M. (1986) Translation Initiation of Bacteriophage Lambda Gene cII Requires Integration Host Factor, J. Bacteriol. 165: 167-174
• Mahajna, J., King, P., Parker, P. and Haley, J. (1995) Autoregulation of Cloned Human Protein Kinase C beta and gamma Gene Promoters in U937 Cells, DNA and Cell Biology 3: 213-222
• Mahajna, J., Shi, B. and Bruskin, A. (1997) A four amino acid insertion in the ligand binding domain inactivates hRXRbeta and renders dominant negative activity. DNA and Cell Biol. 16: 463-476.
• Shi, B., Triebe, D., Kajiji, S., Iwata, K., Bruskin, A. and Mahajna, J. (1999). Identification and characterization of Baxepsilon, a Bax variant missing the BH2 and the TM domains. Biochem Biophys Res Commun 254:779-85.
• Shtayeh S.M., Yaniv Z. and Mahajna, J. (2000). An ethnobotanical survey in the Palestinian area: A preliminary classification of the healing potential of medicinal plants. J. of Ethnopharmacol. 73: 221-232.
• Yassin, M., and Mahajna, J. (2003). Medicinal Mushroom Extracts Selectively Inhibit Proliferation and Induce Differentiation of K562 Human Chronic Myelogenous Leukemia Blast Cells. Int. J. Medicinal Mushroom, 5: 259-274.
• Konson, A., Abed N. Azab, N., A., Ben-Kasus, T., Mahajna, J., Danon, A., Rimon, G. and  Agbaria, R. (2004) Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells in vitro and in vivo. Cancer Gene Therapy 11: 830-940.
• Petrova, R. D., Wasser, S.P., Mahajna, J., Denchev, C.V. and Eviatar, E. (2005). Potential Role of Medicinal Mushrooms in Breast Cancer Treatment: Current Knowledge and Future Perspectives. J. Med. Mush.  7, 135-149.
• Petrova, D.R., Wasser, S.P., Mahajna, J., Cvetomir M. Denchev, M.C. & Nevo, E. (2005). Medicinal Mushrooms: A New Source for Breast Cancer Therapeutics. Intern. J. Med. Mush. 7, 445-446.
• Didukh, Y. M., Wasser, S.P., Nevo, E. & Mahajna, J. (2005) Screening Antitumor Activity of Low-Molecular-Weight Compounds Obtained from the Fruit Bodies of Family Agaricaceae Chevall. (Higher Basidiomycetes). Intern. J. Med. Mush. 7, 398-400.
• Mahajna, J., Yassin, M., Zaidman, B-Z., Nevo, E. and Wasser, S.P. (2005). Medicinal Mushroom Substances As Cancer Molecular Therapy. Intern. J. Med. Mush. 7, 352.
• Zaidman, B-Z., Yassin, M., Mahajna, J. and Wasser, S.P. (2005). Medicinal Mushroom Modulators of Molecular Targets As Cancer Therapeutics. Journal of Applied Microbiology and Biotechnology. 67: 453-468.
• Konson, A., Mahajna, J., Danon, A., Rimon, G. and Agbaria, A. (2006). The involvement of nuclear factor Kappa B in cyclooxigenase-2 expression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene. Cancer Gene Therapy, 13:1093-1104
• Zaidman, B.Z., Lutin, A., Wasser, S.P., Nevo, E. and Mahajna, J. (2007). Adverse effects of mycelia and culture broth extracts from Bjerkandera adusta (Willd.: Fr.) P. Karst. and Hypholoma fasciculare (Huds.: Fr.) P. Kumm. on breast and prostate cancer cells. Intl. J. Med. Mush, 9 (1). 39-46.
• Zaidman, B., Wasser, P.S., Nevo, E. and Mahajna, J. (2007). Androgen receptor-dependent and independent mechanisms mediates Ganoderma Lucidium activity on LNCaP prostate cancer cells. Int J Oncol. 31:959-67.
• Mahajna J., Zaidman, B., Sussan, S., Dotan, N., Wasser, S.P. and Nevo, E. (2007). Mushroom substances as Therapeutics for hormone-refractory prostate cancer. Intl. J. Med. Mush, 9 (3). 212-213.
• Petrova, D., Ruimi, N., Sussan, S., Wasser, S.P., Nevo, E., Reznick, A.Z., and Mahajna, J. (2007). Inhibitory Effects of Marasminus oreades extract Fractions on NF-kB Activation Pathway. Intl. J. Med. Mush, 9 (3). 339-340.
• Zaidman, B., Wasser, P.S., Nevo, A. and Mahajna, J. (2008). Coprinus comatus and Ganoderma lucidum interfere with Androgen Receptor function in prostate cancer cells. Mol Biol Reports 35: 107-117.
• Petrova, R.D., Wasser, S.P., Denchev, C.M.,  Eviatar N., Reznick, A.Z., and Mahajna, J. (2008). Fungal metabolites modulating NF-kB activity: A new approach to cancer therapy and cancer chemoprevention. Oncology Reports 19: 299-308.
• Yassin, M., Wasser, S.P. and Mahajna, J. (2008) Substances from the medicinal mushroom D. Gibbosa inhibit Kinase activity of native and T315I mutated Bcr-Abl. Int. J. Oncol 32: 1197-1204.
• Mahajna, J., Dotan, N., Zaidman, B-Z., Petrova, R.D., and Wasser, S.P. (2009) Pharmacological Values of Medicinal Mushrooms for Prostate Cancer Therapy: The Case of Ganoderma lucidum. Nutrition and Cancer 61: 16-26.
• Petrova, R.D., Mahajna, J., Wasser, S., P., Ruimi, N., Denchev, C.M., Sherbel S., Eviatar N. & Reznick, A.Z. (2009). Marasmius oreades substances block NF-kB activity in MCF7 breast cancer cells through interference with IKK activation pathway. Mol Biol Rep. 36(4):737-44
• Ruimi, N., Rwashdeh, H., Wasser, S.P.,  Konkimalla, B.,   Efferth, T.,  Borgatti, M.,  Gambari, R. and Mahajna, J. (2010). Daedalea  gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-kB and MAPK activities in RAW 264.7 macrophage cells. International Journal of Molecular Medicine 25: 421-432.
• Ruimi, N., Petrova, R.D., Agbaria, R., Sussan, S., Wasser, S.P., Reznick , A.Z. and Mahajna, J. (2010). Inhibition of TNFa-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-kB- and MAPK-dependent mechanisms. Molecular Biology Reports.  37(8):3801-12
• Dotan, N., Wasser, S.P. & Mahajna, J. (2011). Crude extracts from the Culinary-medicinal Mushroom Coprinus comatus as Natural Anti-androgenic Modulators. Integrative Cancer Therapies. Integrative Cancer Therapies 10: 148-159.
• Dotan, N., Wasser, S.P. and Mahajna, J. (2011) Inhibition of the Androgen Receptor Activity by Coprinus comatus Substances. Nutrition Cancer. 63:1316-27.
• Khamaisie, H., Sussan, S., Tal , M.,  Najajreh , Y.,  Ruthardt, M. and Mahajna, J. (2011). Oleic acid is the active moiety in the mushroom Daedalea gibbosa that inhibits Bcr-Abl auto-phosphorylation activity. Anticancer Research. 31: 177-183.
• Mian, A.A., Schüll, M., Oancea, C., Najajreh, Y., Mahajna, J., Goldblum, A., Oliver Gerhard Ottmann, O.G., Beissert, T. and Ruthardt, M. (2011). Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia Chromosome Positive Leukemic Cells. Open Hematology Journal, 5, 21-27
• Asatiani, D.A, Wasser, S.P., Nevo, E., Ruimi, N., Mahajna, J. and Reznick, A.  (2011). Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (O.F.Mull.:Fr.) Pers. (Agaricomycetideae) Substances Interfere with H2O2 Induction of the NF-kB pathway through inhibition of IkBa phosphorylation in MCF7 Breast Cancer Cells. International Journal of Medicinal Mushrooms, 13 (1): 19-25.
• Gochman, E., Mahajna, J. & Reznick, A. (2011). A dual mechanism of NF-κB activation by peroxynitrite through p38 MAP kinase dependent IκBα phosphorylation, versus IκBα nitration in colon cancer cells. Anticancer Research 31: 1607-1617.
• Mian, A.A. , Metodieva, A., Najajreh, Y., Ottmann, O.G., Mahajna, J. and Ruthardt, M. (2012). p185BCR/ABL exhibits a lower sensitivity to the allosteric inhibitor GNF-2 as compared to p210BCR/ABL in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica. 97:251-7.
• Gochman, E., Mahajna, J., Shenzera, J., Dahand, A., Blattd, , Elyakimd, R. and Reznicka, A.Z. (2012).  The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem. Dec;114(8):827-35.
• Mian, A.A., Metodieva, A., Badura, S., Khateb, M., Ruimi, N., Najajreh, Y., Ottmann, G.O., Mahajna, J. and Ruthardt, M. (2012). Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer. 12:411
• Khateb, M., Ruimi, N., Khamaisie, H , Najajreh, Y., Mian, A. A., Metodieva, A., Ruthardt, M. and Mahajna, J. (2012). Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. BMC Cancer, 12:563.
• Najajreh, Y., Khamaisie, H., Ruimi, N., Khatib, S., Katzhendler, J., Ruthardt, M., and Mahajna, J. (2013). Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. Molecular Biology Reports 40(3):2205-13
• Orgil,O., Schwartz, E., Matityahu,I. , Mahajna, J. and Amir,R. (2014). The antioxidative and anti-proliferative potential of non-edible organs of the pomegranate fruit and tree. LWT - Food Science and Technology 58 (2), 571-577.
• Agbarya, A., Ruimi, N., Epelbaum, R., Ben-Arye, E. and Mahajna, J. (2014). Natural products as potential cancer therapy enhancers: A preclinical update. SAGE Open Medicine: 2, 1-12.
• Feitelson, M., Arzumanyan, A., Kulathinal, R., Blain, S., Holcombe, R., Mahajna, J., et al., (2015). Sustained Proliferation in Cancer: Mechanisms and Novel Therapeutic Targets. Semin Cancer Biol. 2015 Apr 17. pii: S1044-579X(15)00014-0. doi: 10.1016/j.semcancer.2015.02.006.
• Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J. (2016). Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer 16(1):140. doi: 10.1186/s12885-016-2182-8.
• Ben-Arye E, Mahajna J, Aly R, Ali-Shtayeh MS, Bentur Y, Lev E, Deng G, Samuels N. (2016). Exploring an herbal "wonder cure" for cancer: a multidisciplinary approach. J Cancer Res Clin Oncol 142(7):1499-508. doi: 10.1007/s00432-016-2175-7.
• Orgil, O, Spector L, Holland D, Mahajna J, Amir R. (2016). The anti-proliferative and anti-androgenic activity of different pomegranate accessions. Journal of Functional Foods 26, 517-528
• Ben-Arye E, Lavie O, Samuels N, Khamaisie H, Schiff E, Gressel Raz O, Mahajna J. (2017). Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach. Medical Oncology, 34(4):54. doi: 10.1007/s12032-017-0910-9.
• Kidan N, Khamaisie H, Ruimi N, Roitman S, Eshel E, Dally N, Ruthardt M, Mahajna J. (2017). Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential. J Cancer, 8(19):3952-3968. doi:10.7150/jca.19633.

Articles or chapters in refereed books:

• Oppenheim, A.B., Mahajna, J., Altuvia, S., Koby, S., Teff, D., Locker-Giladi, H., Hyman, H., and Honigman, A. (1985) Utilization of Lambda Control Elements for Gene Expression Studies in E. Coli, In recombinant DNA Research and Viruses, Becker, Y., ed., Martinus Nijhoff Publishing, Boston, p. 73.

Ruimi, N., Dotan, N., Menachem, N., Bartuv-Tal, J. and Mahajna, J. (2010). Mushroom-derived substances for cancer prevention and treatment. In Bioactive foods and extracts in Cancer Treatment and Prevention. R.R Watson and V.R. Preedy ed, Tylor and Francis Group publishing, Boca Raton, Florida, USA Pages 223-236

Gochman, E., Reznick, AZ., and Mahajna, J. (2013). Involvement of Reactive Nitrogen Species and NF-kB in Colon Cancer. Lab Lambert Academic Publishing, Heinrich-Bocking-Str. 6-8, 66121 Saarbrucken, Deutschland, Germany. (English).

Other publications (in Hebrew):

Hila Tobi-Schwartzman, Yehudit Bartov-Tal, Nesli Dotan, Prof. Wasser Solomon and Jamal Mahajna, "Mushrooms as a Source of Anti-Cancer Substances", published July 31, 2007 in "The Medical"

Books :

• Einat Gochman, Abraham, Z. Reznick and Jamal Mahajna. Involvement of Reactive Nitrogen Species and NF-KB in Colon Cancer. Lab Lambert Academic Publishing (2013), Heinrich-Bocking-Str. 6-8, 66121 Saarbrucken, Deutschland, Germany. (English).

Active Participation in Conferences

Oral Presentation in Scientific Conferences (2005-present):

1. October 2005- the 3rd Third International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Port Townsend, WA USA.
2. March 2007-Frontiers of Science and Engineering 2007 Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Seville, Spain
3. September 2007-The 4th International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer", Ljubljana, Slovenia
4. November 2007-The World Science Forum "Targeting the Myristoyl Binding Pocket (MBP) in Bcr-Abl: A Rational Approach for Designing Therapeutics for CML" Budapest, Hungary
5. October 2008-13th World Congress on Advances in Oncology and 11thInternational Symposium on Molecular Medicine "Overcoming acquired resistance in Gleevec-refractory CML" Crete, Greece.
6. May 2009- Scientists and Scholars: Advancing Human Right "A regional collaboration Project for the Development of Novel CML therapy", Rabat, Morocco.
7. September 2009- The 5th International Medicinal Mushroom Conference " Modulation of iNOS Expression by Medicinal Mushrooms:  Anti-inflammatory and Anti-cancer Potentials", Nantong, China.
8. October 10, 2010. Galilee Biomedical conference. Synthesis, Characterization and In Vitro Efficacy of novel Cisplatin (IV) Pro-drugs that Overcome Intrinsic Resistance of Cisplatin
9. Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia  "Biologically Active Substances from Culinary-Medicinal Mushroom Coprinus comatus as Modulators of Androgen Receptor Activity in Prostate Cancer Cell Lines"
10. Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia  " Oleic acid is the active component in the mushroom Daedalea gibbosa that inhibits Bcr-Abl kinase auto-phosphorylation activity"
11. Oct 6-8, 2011, 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine "Allosteric Inhibitors of Abl kinase as CML therapeutics". Rhodes Island, Greece
12. Oct 25, 2011 2nd Galilee Biomedical Conference, Kiryat Shmona "Allosteric Inhibitors of Abl kinase as CML therapeutics".
13. Sep 13, 2012; The annual meeting of Clinical Nutrition: Nutrition for Cancer starvation.
14. April 19, 2013; Snail overexpression in Ph-positive cells confers drug resistance to AKIs. Laboratory for Tumor Stem Cell Biology, Department of Hematology, J.W. Goethe University, Frankfurt, Germany.
15. May 27, 2013. Mushrooms Substances as Prostate Cancer Therapeutics. Israel Nutrition Week, preventive nutrition, Tel-Aviv.
16. Sep 27, 2103. Snail overexpression confers resistance to Abl kinase inhibitors and collateral sensitivity to Gemcitabine in Ph-positive leukemic cancer cells. ECCO 17 - 38th ESMO- 32nd ESTRO European Cancer Congress, Amsterdam.
17. August 31 2015, MEDINICAL MUSHROOMS TO OVERCOME AQUIRED RESISTANE IN PH POSITIVE LEUKEMIA. The first International Conference on Natural Product for Cancer Prevention and Therapy. Istanbul, Turkey.
18. Oct 8, 2015, Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. 20th World Congress on Advances in Oncology and  18th International Symposium on Molecular Medicine, Athens, Greece

Posters presented in scientific conferences (2005-present):

1. Zaidman BZ, Mahajna J, Wasser SP. Poster presented at the 4th Congress of the Federation of the Israel Societies for Experimental Biology, February 2005, Eilat, Israel. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer".
2. Mahajna J., Zaidman BZ,  Wasser SP. Poster presented at the 3rd International Medicinal Mushroom Conference, October 2005, Port Townsend, Washington, USA. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer".
3. Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in the 4th International medicinal mushroom conference, Sep 2007, Ljubljana, Slovenia. "Inhibitory Effects of Marasmius oreades Extract Fractions on NF-kB Activation Pathway".
4. Nili Ruimi, Solomon Wasser and Jamal Mahajna. Poster presented in ISOFRR 2007. The 23th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Tel Aviv University, Israel.
5. Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in FISEB 2008, Eilat, Israel. "Inhibitory Effects of Marasmius oreades Fractions on NF-kB Activation Pathway".
6. Nili Ruimi,  Haithem Rwashdeh , Solomon Wasser and Jamal Mahajna Poster presented in ISOFRR 2008. The 24th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Wingate Institute, Israel. " Modulation of iNOS expression by medicinal mushrooms:  anti-inflammatory and anti-cancer potentials".
7. Gochman E, Mahajna J, Reznick A.Z. Poster presented in the Federation of European Biochemical Societies (FEBS) "Mechanisms, Consequences and Detection of Free Radical-Mediated Oxidative Protein Modification". April 2009, Antalya, Turkey. "The involvement of Reactive Nitrogen Species (RNS) in modulating transcription factor NF-κB and MAP kinases (MAPKs) pathways in colon cancer cells".
8. Riad Agbaria, A Konson , JA Mahajna , G Rimon. Poster presented in The 6th Annual Conference of the ISGCT. May 4, 2009. Ben Gurion University, Beer-Sheva, Israel. "effect of Herpes simplex virus thymidine kinase gene transduction on tumor cell biology
9. Dotan, N, Wasser, S and Mahajna, J " The 5th International Medicinal Mushroom Conference-Sep 2009, Nantong, China "Crude Extracts from the Culinary-medicinal Mushroom Coprinus comatus influence Androgen Receptor activity in Prostate Cancer cell line Mushroom".
10. Einat Gochman, Jamal Mahajna and Abraham Reznick in the 25th annual meeting of the Israeli Society for Oxygen and free Radical research" Dec 13, 2009. A dual mechanism of NF-kB activation by peroxynitrite through p38 MAP kinase dependent IKBa-phosphorylation, versus IKBa nitration in colon cancer cells.
11. Afsar Mian, Anna Metodieva, Yousef Najajreh, Hubert Serve1, Oliver Ottmann, Jamal Mahajna  and Martin Ruthardt , in the 52nd ASH Annual Meeting and Exposition, December 4-7, 2010. The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL
12. Hazem Khamaisi, Mamduh Khatteb, Linda Braik, Nida Eghreib, Amiram Goldblum, Martin Ruthardt, Yousef Najajreh, Jamal Mahajna , in the 6th FISEB, Feb 7-10,2011.Myristate analogs as BCR/ABL allosteric inhibitors for the treatment of Philadelphia positive leukemia
13. Einav Ratzon ,  Yousef Najajreh , Rami Salem,  Nili Ruimi,  Linda Braik  , Hazem Khamaisi,  Martin Ruthardt,  Jamal Mahajna, in the 6th FISEB, Feb 7-10, 2011. Synthesis, characterization and in vitro efficacy of novel Cisplatin-IV pro drugs overcoming intrinsic resistance to Cisplatin
14. Nili Ruimi ,Mamduh Khatteb, Yousef Najajreh, Martin Ruthardt, Jamal Mahajna, the 6th FISEB, Feb 7-10, 2011. Cooperation between GNF-2 and Abl kinase inhibitors (AKIs) in overcoming BCR/ABL T315I mutation
15. Nesly Dotan , Hazem Khamaisi, Solomon P. Wasser, Jamal Mahajna, in the 6th FISEB, Feb 7-10, 2011. Biologically active substances from culinary-medicinal mushroom Coprinus Comatus as modulators of androgen receptor activity in prostate cancer cell lines
16. Sani Kast, N., J. Mahajna, Y. Najajreh, M. Ruthardt and A. Goldblum (2011).  In the 9th International Conference on Chemical Structures, June 5-9 2011, Noordwijkerhout. The Netherlands. New Types Of Alloseric Inhibitors Against Bcr-Abl, Using Multiple Pharmacophore Models
17. Mamduh Khateb, Yousef Najajreh, Martin Ruthardt and Jamal Mahajna (2012). In Molecular Targeted Therapies: Mechanisms of Resistance, May 9-12 San Diego, Ca, USA.  Overcoming acquired resistance in Ph + leukemia.
18. Mahajna, J., Khamaisie, H., Ruimi, N., Agbarya, A., Eshel, E., Dally, N., Mian, AA, and Ruthardt, M. (2014). 794: Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia. July 5-8, Munich, Germany. EACR meeting.
19. O Regev, N Kidan, H Khamisie, J Mahajna (2016). Crizotinib overcomes microenvironment mediated drug resistance in Ph positive leukemia. July 8-12, Manchester, UK (European Journal of Cancer, S92-S93).
20. Jamal Mahajna, Noa Kidan, Hazem Khamaisie and Martin Ruthardt (2017). Ectopic expression of Snail and Twist in Ph+ leukemia cells upregulates CD44 expression and alters their differentiation potential. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Estoril Congress Centre, Estoril, Portugal – October 12-15, 2017.

https://www.researchgate.net/profile/Jamal_Mahajna